Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVDLNASDAQ:MBIONASDAQ:MISTNASDAQ:RTTRNASDAQ:XOMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$17.98+0.9%$15.81$9.50▼$18.85$1.63B1.61.21 million shs142,710 shsMBIOMustang Bio$0.33-5.8%$0.94$0.32▼$8.17$3.43M1.58175,758 shs134,266 shsMISTMilestone Pharmaceuticals$1.61+1.9%$1.67$1.33▼$4.49$85.57M1.77305,278 shs96,536 shsRTTRRitter Pharmaceuticals$0.30-3.9%$2.99$0.15▼$1.27$13.71M-0.4314.23 million shs17,611 shsXOMAXOMA$25.08-1.1%$24.80$13.48▼$27.00$291.93M0.5820,627 shs2,694 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+0.91%+2.53%+9.73%+28.85%+77.49%MBIOMustang Bio+2.11%-3.64%-61.60%-75.00%-90.81%MISTMilestone Pharmaceuticals-4.79%-2.45%-12.15%+3.25%-57.14%RTTRRitter Pharmaceuticals-3.85%-4.72%-25.94%-41.20%-66.63%XOMAXOMA-1.09%+3.13%+9.55%+25.61%+32.08%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals1.9226 of 5 stars3.51.00.00.03.01.70.6MBIOMustang Bio2.3774 of 5 stars3.55.00.00.03.30.00.0MISTMilestone Pharmaceuticals2.9187 of 5 stars3.45.00.00.02.82.50.0RTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXOMAXOMA3.5122 of 5 stars3.51.00.03.02.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals3.00Buy$22.5725.54% UpsideMBIOMustang Bio3.00Buy$17.255,127.27% UpsideMISTMilestone Pharmaceuticals2.75Moderate Buy$10.75567.70% UpsideRTTRRitter PharmaceuticalsN/AN/AN/AN/AXOMAXOMA3.00Buy$74.00195.06% UpsideCurrent Analyst RatingsLatest RTTR, XOMA, MIST, MBIO, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.004/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/22/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024MISTMilestone PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.002/26/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.002/16/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$27.96M58.25N/AN/A$0.98 per share18.35MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AMISTMilestone Pharmaceuticals$1M85.57N/AN/A$0.50 per share3.22RTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/AXOMAXOMA$4.76M61.33N/AN/A$7.72 per share3.25Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A21.15N/AN/A-198.06%-84.51%5/2/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)RTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/AXOMAXOMA-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)Latest RTTR, XOMA, MIST, MBIO, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023MISTMilestone Pharmaceuticals-$0.30-$0.32-$0.02-$0.32N/AN/A3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 million3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A3.643.36MBIOMustang BioN/A0.740.74MISTMilestone Pharmaceuticals2.9710.1110.11RTTRRitter PharmaceuticalsN/A3.673.67XOMAXOMA1.348.688.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%MBIOMustang Bio9.95%MISTMilestone Pharmaceuticals86.18%RTTRRitter Pharmaceuticals0.84%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.00%MBIOMustang Bio2.10%MISTMilestone Pharmaceuticals10.40%RTTRRitter Pharmaceuticals15.40%XOMAXOMA7.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableMISTMilestone Pharmaceuticals4753.15 million47.62 millionOptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableXOMAXOMA1311.64 million10.80 millionOptionableRTTR, XOMA, MIST, MBIO, and AVDL HeadlinesSourceHeadlineXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)finance.yahoo.com - April 25 at 8:40 AMXOMA's (XOMA) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - April 25 at 8:09 AMXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)globenewswire.com - April 25 at 7:30 AMXOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30americanbankingnews.com - April 25 at 3:14 AMActym Therapeutics Appoints Thomas Smart as CEOprnewswire.com - April 24 at 9:00 AMXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsfinance.yahoo.com - April 20 at 9:43 AMXOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93americanbankingnews.com - April 17 at 2:58 AMXOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLCmarketbeat.com - April 9 at 9:43 PMXOMA Corporation Announces Closing of Tender Offerglobenewswire.com - April 3 at 9:00 AMXOMA Declares Quarterly Preferred Stock Dividendsglobenewswire.com - March 21 at 7:30 AMXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.globenewswire.com - March 19 at 4:05 PMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 8 at 1:03 PMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valuefinance.yahoo.com - March 8 at 7:51 AMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valueglobenewswire.com - March 8 at 7:30 AMXOMA to Present at Upcoming Investor Conferences in Marchglobenewswire.com - February 28 at 7:30 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMCompare with Maple Leaf Green World Inc (4HV0)msn.com - February 18 at 12:30 PMXOMA to acquire Kinnate Biopharmathepharmaletter.com - February 17 at 10:21 AMXOMA Mar 2024 20.000 putfinance.yahoo.com - February 17 at 10:21 AMXOMA Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:21 AMBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharmabenzinga.com - February 16 at 1:37 PMXOMA Agrees to Acquire Kinnate Biopharmamarketwatch.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsAll Headlines Company DescriptionsAvadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Milestone PharmaceuticalsNASDAQ:MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Ritter PharmaceuticalsNASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.